Sopharma's (

) consolidated H1 profit stands at 11.547 mn leva (5.9 mln euros), of which the group account for 11.46 mln leva. This is 43.5% down from June 2007 (the decline for the subsidiaries is 42.7%).

Sales of goods brought the most revenues (71%). They are also 59% up on year. Production sales are at the same time decreasing by 11% to 54.9 mln leva. Total revenues of the group stand at 220.5 mln leva, which is a 31% hike y/y.

Operating costs rose 39.5%. The products' prime cost accounts for the largest part of total costs (60%).

Costs on materials represent are up by 10.807 mln leva to 18% of all. Payroll costs are up by 5.65 mln and form 10% of all. External services (11%) are up by 6.799 mln leva.

Net financial costs rose by 2.111 mln leva s a result of changes in forex operations and interests on bank loans. Taxes are down by 992,000 leva.

The group's assets increased by 100.02 mln leva to 496 mn leva (253.6 mln euros). Properties, machines and equipment account for 70% of fixed assets.

Sopharma's core capital stands at 132 mn leva (67.4 mln euros) and equity capital is at 238.6 mln leva (121 mln euros).

Main shareholders are Donev Investments (25.64%), Gramercy Emerging Markets Fund (17.08%), telso Jsc (13.77%) and Financial Consultants Company (10.04%).

The last transaction on the position today was at 4.35 leva.